CellKey AI’s Multi-Omics Analysis Service is an advanced platform that integrates proteomics, glycoproteomics, and metabolomics to deliver comprehensive insights for biomarker discovery, precision diagnostics, therapeutic target identification, and disease mechanism research.

Leveraging high-resolution LC-MS/MS technology, our service enables in-depth profiling of biological samples—such as plasma, tissue, and cells—by detecting protein expression patterns, site-specific glycosylation structures, and metabolite composition changes.
These multi-layered datasets are further processed and interpreted using our proprietary AI-based data analysis platform, which supports quantitative analysis, statistical interpretation, and functional annotation in a streamlined workflow.

A key strength of our platform lies in its glycoproteomics capabilities, which can uncover disease-specific glycosylation signatures often missed by conventional proteomics alone. This makes our service particularly valuable for oncology, immunology, metabolic diseases, and rare disease research.

We also offer tailored services for pharmaceutical companies and clinical researchers, including companion diagnostic biomarker discovery, clinical sample analysis, and data-driven drug target validation.

By combining analytical precision with intelligent interpretation, CellKey AI’s Multi-Omics Analysis Service provides a powerful and scalable solution for extracting meaningful insights from complex biological data.